Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Non-Small Cell Lung Cancer
Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have not received prior chemotherapy will be treated with erlotinib 150 mg once a day and sorafenib 400 mg twice a day.
- Trial name
- NCT00722969
- Testing
- sorafenib + erlotinib
- Where
- 4 sites in Netherlands
- Volunteers
- 48 people
- Sponsor
- Universitair Ziekenhuis Brussel
Non Small Cell Lung Cancer, Lung Cancer
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II
- Trial name
- NCT03999710
- Testing
- Radiation Therapy, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC Stage IV, EGFR Gene Mutation
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
- Trial name
- TROP-LUNG (NCT07548060)
- Testing
- sacituzumab tirumotecan
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer
Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if escalated/accelerated proton radiotherapy can improve the control of Non-Small Cell Lung Cancer (NSCLC) and decrease side effects.
- Trial name
- NCT00495040
- Testing
- Proton Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread…
- Conditions
- Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT03493789
- Testing
- Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Emory University
Lung Neoplasms, Squamous Cell Lung Cancer
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
This phase II trial studies how well icotinib works in treating patients with completely resected stage IB NSCLC harboring EGFR mutation.
- Conditions
- Lung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
- Trial name
- CORIN (NCT02264210)
- Testing
- Icotinib
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Sun Yat-sen University
Dysphagia, Lung Cancer
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain.
- Conditions
- Dysphagia, Lung Cancer, Pain, Esophagitis
- Trial name
- NCT01262560
- Testing
- Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
- Where
- 59 sites in United States
- Volunteers
- 163 people
- Sponsor
- Radiation Therapy Oncology Group
Non Small Cell Lung Cancer, Lung Cancer
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
A study to measure the safety and effectiveness of S-3304 when given in combination with conventional chemo-radiation therapy in patients with locally advanced non-small cell lung cancer.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
- Trial name
- NCT00078390
- Testing
- S-3304, Chemo-irradiation
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Shionogi
Non-small Cell Lung Cancer, Hiv-positive
Chemotherapy for Lung Cancer in HIV-positive Patients
This is a phase II, multicenter, non-randomized, open-label study evaluating the combination of pemetrexed plus carboplatin in HIV-positive patients with lung cancer.
- Trial name
- CHIVA (NCT01296113)
- Testing
- Chemotherapy
- Where
- 40 sites in France
- Volunteers
- 61 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer, Non Small Cell Lung Cancer
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer…
- Trial name
- NCT00687297
- Testing
- vandetanib induction, Docetaxel, Carboplatin
- Where
- 30 sites in United States
- Volunteers
- 162 people
- Sponsor
- PrECOG, LLC.
Non-Small Cell Lung Cancer, Stage IIIB or IV
Alimta and Gemcitabine in Non-Small Cell Lung Cancer
The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of a randomized trial, and (2) to compare the…
- Trial name
- ANGEL (NCT00434135)
- Testing
- gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Southern Italy Cooperative Oncology Group
Non Small Cell Lung Cancer
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
This is a randomized, controlled, double-blind, single-center Phase III clinical study in patients with EGFR/ALK mutation negative stage II-IIIB (N2) non-small cell lung cancer (NSCLC) after complete tumor resection.
- Trial name
- NCT04772287
- Testing
- Toripalimab
- Volunteers
- 341 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
This phase I trial studies docetaxel, cisplatin, and erlotinib hydrochloride in treating patients with stage I-III non-small cell lung cancer following surgery.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Trial name
- NCT00254384
- Testing
- Cisplatin, Docetaxel, Erlotinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety of accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) concurrent with chemotherapy for patients with unresectable stage III non-small…
- Trial name
- NCT02720614
- Testing
- Hypofractionated radiation/chemotherapy
- Volunteers
- 12 people
- Sponsor
- LIN QIANG
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV…
- Trial name
- NCT01519804
- Testing
- cisplatin/carboplatin, onartuzumab, paclitaxel
- Where
- 69 sites in United States, Argentina and 7 more
- Volunteers
- 108 people
- Sponsor
- Genentech, Inc.
Lung Cancer
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have stage IIIB…
- Trial name
- NCT00005037
- Testing
- temozolomide
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
This phase II trial tests how well cemiplimab works in treating patients with PD-L1 >= 50% non-small cell lung cancer (NSCLC) that has spread from where it first started (primary site) to the brain (metastases).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT05840770
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer, Squamous Cell Carcinoma
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
This randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell…
- Trial name
- CIK (NCT01631357)
- Testing
- CIK cell, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT04984811
- Testing
- efineptakin alfa, Atezolizumab
- Where
- 22 sites in United States
- Volunteers
- 33 people
- Sponsor
- NeoImmuneTech
Lung Cancer
Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether giving chemotherapy in addition to standard therapy is a more effective treatment for…
- Trial name
- NCT00003240
- Testing
- cisplatin, ifosfamide, mitomycin C
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.